| Product NDC: | 33261-419 |
| Proprietary Name: | Acyclovir |
| Non Proprietary Name: | Acyclovir |
| Active Ingredient(s): | 200 mg/1 & nbsp; Acyclovir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 33261-419 |
| Labeler Name: | Aidarex Pharmaceuticals LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA074578 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19970423 |
| Package NDC: | 33261-419-30 |
| Package Description: | 30 CAPSULE in 1 BOTTLE (33261-419-30) |
| NDC Code | 33261-419-30 |
| Proprietary Name | Acyclovir |
| Package Description | 30 CAPSULE in 1 BOTTLE (33261-419-30) |
| Product NDC | 33261-419 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Acyclovir |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19970423 |
| Marketing Category Name | ANDA |
| Labeler Name | Aidarex Pharmaceuticals LLC |
| Substance Name | ACYCLOVIR |
| Strength Number | 200 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |